SVMPharma’s real-world studies in diabetic eye oedema led to multiple successful publications and congress presentations in the UK and Europe

SVMPharma has recently collected real-world data in the UK and Europe for which has lead to successful outcomes from publications to presentations in a major European congress

Click on the references below to find out more

FINAL RWE36 ICE infographic without references

References

(1) Currie CJ. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 33-43.

(2) Holden SE. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 5-17.

(3) Holden SE. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 45-52.

(4) Currie CJ. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Current Medical Research and Opinion 33:sup2, pages 19-31.

(5) C. Currie, S. Holden, D. Owens. Evaluation of the clinical effectiveness in routine practice of the fluocinolone acetonide intravitreal implant in patients with diabetic macular oedema. Euretina 2017

(6) A. Carneiro, A. Meireles, J. Castro Sousa, C. Teixeira. A retrospective cohort study of the clinical outcomes of ILUVIEN® in four ophthalmology centres in Portugal: The results of the ILUVIEN® clinical evidence study in the Portugal (ICE-PT). Euretina 2018.

Acknowledgements:

The presentations in Euretina were written by Alimera Sciences Limited in consultation with the respective co-authors 5-6

 

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Posted in Blogs.